Naltrexone is a pure antagonist at the µ-opioid receptor, with no intrinsic agonist effects 1 . It was licensed for use in Australia in its oral form by the Therapeutic Goods Authority in 1999 for the management of alcohol abuse and the maintenance of opioid-dependent patients who have ceased the use of opioids. Since 2001, subcutaneous naltrexone implants have been available in Australia as unapproved therapeutic goods under the Therapeutic Goods Authority Special Access Scheme for the treatment of substance addiction. In Western Australia, it is estimated that 4500 treatments with naltrexone implants were carried out between 2001 and 2008 for the indications of opioid, alcohol or amphetamine dependence and occasionally for impulse-control disorders (personal communication, Aoud et al 2 and Yasui et al , 3 ). Go Medical™ (Go Medical Industries Pty Ltd, Subiaco, WA) naltrexone implants consist of multiple sustained-release pellets that are inserted under local anaesthetic into the sub-cutaneous tissue of the lower abdomen.
Patients present for removal of naltrexone implants due to infection or irritation at the insertion site, naltrexone intolerance or the requirement for effective opioid analgesia for comorbid conditions. Anticipated problems when administering anaesthesia to these patients include ineffective analgesia at usual opioid doses and the potential for opioid overdose, once naltrexone plasma concentration falls below the therapeutic level after implant removal. A plasma naltrexone concentration of less than 1 ng/ml is capable of antagonising the effects of 15 mg of intramuscular morphine 4 and the time-profile of plasma concentration after removal of a subcutaneous implant is unknown 1 . Complicating matters, these patients are likely to have abnormalities in pain perception 5 and some anaesthetists may be reluctant to administer opioid analgesia to those who are currently abstinent.
The aim of this study was to determine the frequency of anaesthesia-related adverse events in patients undergoing removal of naltrexone implants.
SUMMARY
Naltrexone implants are used as an abstinence therapy for patients with opioid, amphetamine and alcohol abuse. This study was designed to assess the implications of this therapy in patients presenting for anaesthesia for removal of these implants. We conducted a retrospective case-note review of 37 patients undergoing removal of naltrexone implants in the period 2001 to 2008 at Sir Charles Gairdner Hospital. Indications for removal included infection at the insertion site, naltrexone intolerance or the requirement for effective opioid analgesia. Thirty-two patients had surgery under general anaesthesia, four under local anaesthesia and one under spinal anaesthesia. The perioperative opioid requirement varied from 0 to 100 mg of intravenous morphine equivalents (median 11.7 mg, mean 20.7 mg). The only factor that was associated with a higher perioperative opioid requirement was whether the implant was infected or not. Forty-four percent of patients having a general anaesthetic complained of moderate to severe pain postoperatively, and 64% of these patients had a prolonged stay in the post-anaesthesia care unit. We did not observe any instances of postoperative complications due to increased opioid sensitivity after removal of naltrexone implants. The majority of patients were discharged home by the first postoperative day. Anaesthesia for the removal of naltrexone implants was associated with a wide range of opioid analgesia requirements and a high incidence of pain postoperatively. Concern regarding increasing opioid sensitivity after removal of implants does not seem to preclude use of generous opioid analgesia in this group of patients. 
METHODS
With research governance ethics approval, we searched the operating theatre management system database to identify patients who had presented for removal of naltrexone implants between 1 January 2001 and 31 December 2008. A retrospective medical record analysis was performed for each procedure. The following patient data were collected: age, gender, indication for implant insertion, indication for implant removal and implant age, co-morbid medical conditions and usual medications. The following procedure data were collected: anaesthetic technique, duration of surgery, post-anaesthesia care unit (PACU) length of stay and complications, perioperative analgesic requirements (from commencement of anaesthesia to discharge from the PACU), analgesic requirements from PACU discharge to hospital discharge and length of hospital stay. Opioid requirements were compared by converting intravenous and oral opioid doses into equivalents of intravenous morphine using an equianalgesic table (10 mg intravenous morphine assumed equivalent to 100 µg intravenous fentanyl, 300 mg intravenous tramadol or 20 mg oral oxycodone 6 ).
Non-normal interval data were analysed with the Mann-Whitney U test, while dichotomous data were analysed with Fisher's exact test. A P value <0.05 was considered statistically significant.
RESULTS
There were 37 procedures for removal of naltrexone implants in 36 patients, with one patient having implants removed as a two-stage procedure.
The mean age was 31 years (range 17 to 48), and 21 of 36 patients were female. Indications for implant insertion were opioid addiction (29 patients), alcohol addiction (four patients) and amphetamine abuse (three patients), although some patients had a history of multiple substance abuse.
The most common indication for implant removal was infection at the insertion site (21 of 37 cases). In the remainder of cases the implants were removed because of irritation at the site of insertion (eight cases), side-effects of naltrexone (nausea and vomiting, weight loss or change in mood; six cases) or a requirement for opioid analgesia for co-morbid conditions (one acute trauma and one chronic rheumatological condition). The median time since implant insertion (age) was 60 days (range 10 to 670) and there was no statistically significant difference in implant age when the indication for removal was considered (infected versus non-infected; P=0.36). Taking into consideration implant dose and age, we estimated whether the patient was likely to have had a therapeutic naltrexone concentration at the time of surgery 2 . According to this analysis, 24 patients were expected to have had therapeutic naltrexone concentrations, 10 patients inactive implants, and for three patients we were uncertain (due to possible variations in implant dose and an implant age close to expiry periods). Three of the patients with inactive implants were taking oral buprenorphine for opioid dependence.
Thirty-two patients had surgery under general anaesthesia, all spontaneously breathing with a laryngeal mask, except for one patient who was in the second trimester of pregnancy and had an endotracheal tube placed. Twenty-four of these patients also received supplemental local anaesthetic infiltration at the site of the surgical wound or a regional block (transversus abdominis plane or ilioinguinal/iliohypogastric block). Four patients had surgery under local anaesthetic infiltration alone (one who was in the third trimester of pregnancy), and one had surgery under spinal anaesthesia (because of a recent upper respiratory tract infection).
Patients required a morphine-equivalent intravenous dose of between 0 and 100 mg (median 11.7 mg; mean 20.7 mg) in the perioperative period. Ten patients (27%) required a morphine-equivalent dose of more than 30 mg.
The mean duration of surgery was 33 minutes, with a range of 15 to 70 minutes. The mean duration of stay in the PACU was 46 minutes (range 0 to 100). Of all but one of the 10 patients whose PACU stay was longer than 60 minutes, uncontrolled pain appears to have been the reason for the prolonged stay.
Of the patients who had the procedure under general anaesthesia, 14 (44%) reported moderate to severe pain in the PACU (numerical rating scale score 4 or greater). Nine of these 14 patients (64%) went on to have a prolonged stay (>60 minutes) in the PACU. The incidence of pain was not influenced by the presence or absence of local anaesthetic infiltration or regional block (10/24 patients (42%) versus 4/8 patients (50%); P=0.29). None of the patients who had the implant removed solely under local or spinal anaesthesia suffered moderate to severe pain in the PACU or subsequently.
The opioid dose administered to patients with infected implants was greater than that for patients whose implants were removed for other indications (median 25.0 mg vs 5.0 mg; P=0.007, Figure 1) . These patients were also more likely to report moderate to severe pain (12/21 versus 2/16 patients; P=0.006) and their duration of stay in PACU was longer (mean 57 vs 31 minutes; P=0.002). This result adVerse eVents in tHe reMoVal oF naltrexone iMplants Anaesthesia and Intensive Care, Vol. 39, No. 5, September 2011 persisted even when those who had the procedure under local or regional anaesthesia were excluded from analysis (59 vs 40 minutes, P=0.013).
Only four patients required parenteral analgesia after discharge from the PACU. Two were prescribed patient-controlled fentanyl analgesia for approximately 12 hours each, one had a ketamine infusion for 12 hours and one had intramuscular pethidine for dressing changes.
There was no association between the age of implants and perioperative opioid requirements, even when predicted implant pharmacological activity (based on implant dose and age) was considered ( Figure 2 ).
There were no instances of postoperative complications due to increased opioid sensitivity after removal of naltrexone implants. One patient had a prolonged PACU stay due to delirium. This patient did not receive any opioid agonists in the perioperative period, but did receive ketamine. Nine (28%) of the patients who underwent general anaesthesia received prophylactic anti-emetics. No patient suffered postoperative nausea or vomiting.
Fifteen patients were managed as day-case patients, with domestic nursing service follow-up for wound dressings. A further 16 were discharged on the first postoperative day. Only three patients remained as inpatients for more than two postoperative days: one was an inpatient for four days for wound management, one was convalescing after an acute trauma (the indication for removal of the implant; discharged on the seventh postoperative day), and one had her postoperative course complicated by the development of an abscess at the wound site and a central line infection (discharged day 30 postoperatively).
DISCUSSION
We report the removal of 37 naltrexone implants between 10 and 670 days after implantation. With the increasing use of subcutaneous naltrexone implants in Australia, it is more likely that anaesthetists will come across these patients in their routine practice. Although no exact plasma concentration has been determined to be effective, a level between 1 and 2 ng/ml is accepted as that providing therapeutic coverage against typically used amounts of heroin and that which limits the effectiveness of opioid analgesics 2 . The 1.1 g, 2.2 g or 3.3 g subcutaneous naltrexone implants maintain blood levels above 2 ng/ml for 95, 136 and 145 days, respectively 2 . However, the duration of opioid resistance after removal of subcutaneous naltrexone implants is unknown 1 .
Perioperative opioid use (equivalents of intravenous morphine in mg)
Major concerns anticipated in these patients were opioid side-effects. Nausea and vomiting are known side-effects of naltrexone, as they are of opioid agonists commonly administered in the perioperative period. It was reassuring and perhaps surprising to find that there was no instance of nausea or vomiting. Despite the administration of up to an equivalent of 35 mg of intravenous morphine, as well as the removal of the protective naltrexone implants, there was no instance of respiratory complications. Our patients did not suddenly become opioid sensitive after removal of their naltrexone implants. However, only four patients required parenteral analgesia after discharge from the PACU. This may reflect the minimal amount of tissue injury in surgery for removal of these subcutaneous implants and limited our ability to detect opioid sensitivity in the later postoperative course.
Administration of opioids was effective in providing postoperative analgesia despite the presence of therapeutic naltrexone plasma concentrations in the majority of patients, suggesting that competitive blockade can be overcome. There was a correlation between peripheral nociception and opioid consumption, as indicated by the observation that patients with infected implants had greater perioperative opioid requirements. However, an unexpected result was the large number of patients who experienced moderate to severe pain in the PACU, despite the frequent use of co-analgesia with non-opioid adjuncts and local or regional anaesthesia. It may be that local anaesthetic infiltration was less effective in some patients due to the presence of infection at the site of surgery.
There was no association between perioperative opioid requirements and implant age; nor does it seem that opioid requirements in these patients can be predicted by considering implant dose and implant age to decide whether implants are likely to be active or inactive. It may be that abnormalities in pain perception or abnormal pain behaviours in this group of patients overwhelmed any differences in opioid sensitivity due to naltrexone antagonism or that the minor nature of surgery failed to demonstrate differences in analgesic requirements. The study was also limited by the small number of patients whose implants were beyond the expected expiry age, and may have been confounded by the fact that three were taking an alternative maintenance drug for opioid dependence (buprenorphine). A prospective study with standardised surgical and anaesthetic techniques would be required to more clearly elucidate the clinical time-course of opioid sensitivity once naltrexone implants start to be depleted.
Our findings suggest that it is safe to perform removal of naltrexone implants using liberal opioid analgesia without access to high dependency facilities and that day surgery is feasible. However, postoperative pain was relatively common and associated with a prolonged PACU stay.
